Current Challenges in CAR T Manufacturing

CAR T therapy has undergone a remarkable transformation over the past decade, moving from an experimental treatment to a clinically validated therapeutic platform with seven FDA-approved therapies and a growing global market. Yet despite its success, manufacturing remains a major bottleneck to wider patient access. The challenge now is not clinical validation, but scalable delivery.

Manufacturing limitations stem from donor variability, patient-specific production, and complex multi-step workflows in tightly controlled GMP environments. These factors drive up costs, increase process variability, and limit manufacturing throughput, ultimately restricting access to potentially life-saving therapies. Existing analytical approaches often come too late to provide timely interventions, making it difficult to predict manufacturing outcomes and maintain process control.

The industry now faces the challenge of moving from reactive manufacturing to predictive control. Cytomos has developed AuraCyt, a predictive cell intelligence platform that aims to address this challenge by revealing cellular states earlier in the manufacturing process. AuraCyt uses ultra-wideband dielectric spectroscopy to capture the electrical response of individual cells, which reflects their intrinsic physical state.

By generating high-dimensional digital fingerprints of every cell, AuraCyt provides a biophysics-first route to predictive cell intelligence. In a case study focused on transduction efficiency and process risk, AuraCyt was evaluated in a CAR T manufacturing workflow. The platform identified distinct dielectric signatures associated with donor T cells, T-cell activation, and CAR-CD34 transduction.

This early identification of cellular states provided valuable insights into manufacturing outcomes, demonstrating the potential of predictive cell intelligence to improve manufacturing robustness, reduce costs, increase capacity, and expand patient access to advanced cell therapies.